Journal of Clinical Oncology
Articles in this Issue
Myopathic syndromes and immune checkpoint inhibitors: A systematic review.
e14580 Background: Though ICIs are a breakthrough in advanced cancer treatment, their side effects are often overlooked. This study identifies the prevale...
A phase I study of the EZH2 inhibitor TR115 in patients with relapsed/refractory non-Hodgkin's lymphomas and advanced solid tumors.
7053 Background: EZH2 gain-of-function mutations and overexpression lead to aberrant H3K27me3 levels and result in tumorig...
Exploring the causes of failures in oral leukoplakia clinical trials.
e18087 Background: A proportion of oral cancers arise from oral leukoplakia (OL), a disorder characterized by white plaques with variable malignant transf...
Final overall survival analysis for a phase 3 randomized trial comparing afatinib to chemotherapy in treatment-naïve non-small cell lung cancer with a sensitizing uncommon epidermal growth factor receptor mutation (ACHILLES/TORG1834).
8623 Background: The phase 3 randomized trial comparing afatinib to chemotherapy in treatment-naïve non-small cell lung cancer (NSCLC) with a sensitizing...
Healthcare disparities in Merkel cell carcinoma (MCC) in immune checkpoint inhibitor (ICI) era: A SEER study of survival disparities in older adults.
e21602 Background: MCC is an aggressive type of neuroendocrine skin cancer, with an incidence of 1.0 to 9.8 (per 100,000 person-years) in adults aged 60–6...
Peripheral eosinophilia as a potential biomarker of response and immune-related adverse events in patients with gastrointestinal tumors treated with immune checkpoint inhibitors: A single-center experience.
e15697 Background: Peripheral eosinophilia (PEBC), defined as an absolute eosinophil count (AEC) > 0.5 × 10⁹/L, has emerged as a biomarker in solid tum...
Evaluating the prognostic utility of cell-free (cf)DNA tumor fraction (TF) in metastatic castration-resistant prostate cancer (mCRPC).
5052 Background: Accurate prognostication is essential for guiding treatment decisions. cfDNA TF provides a non-invasive quantitative assessment of tumor...
Food insecurity and disparities in mental health symptoms and severity among breast cancer survivors.
1581 Background: Breast cancer survivors (BCS) often experience mental health challenges during survivorship. Food insecurity is a growing public health c...
RAS/BRAF testing of circulating cell-free DNA (cfDNA) in RAS/BRAF wild-type (RAS/BRAF <sup>WT</sup> ) metastatic colorectal cancer (mCRC) patients: Preliminary results of the phase III LIBImAb study.
e15570 Background: The LIBImAb Study is a Phase III, randomized, open-label, comparative, multicenter trial designed to assess the efficacy in terms of pr...
Dysregulation of DNA damage repair in lung cancer driven by <i>MTAP</i> loss: Mechanistic insights and target discovery.
8602 Background: MTAP loss leads to methylthioadenosine (MTA) accumulation, disrupting downstream metabolic pathways. Targeting synthetic leth...
DB-1311/BNT324 (a novel B7H3 ADC) in patients with heavily pretreated castrate-resistant prostate cancer (CRPC).
5015 Background: There is a high unmet need for effective therapy for patients (pts) with heavily pretreated CRPC. B7H3 ADCs have reported early clinical...
Trends and disparities in cardiovascular mortality among patients with hematological malignancies: A 22-year CDC-WONDER analysis (1999-2020).
e23177 Background: Hematological malignancies (HM) are the fourth most diagnosed cancer in developed countries, with rising incidence. Patients with HM fa...
Economic impact and mortality outcomes of palliative care integration among cancer patients: Analysis of National Inpatient Sample 2018-2022.
12031 Background: While palliative care integration into oncology represents a quality metric, its relationship with mortality outcomes and cost implicati...
Long-term oncologic outcomes in elderly patients with localized anal cancer.
e15502 Background: Localized anal cancer (LAC) is a rare malignancy, with limited data on treatment tolerance and outcomes in elderly patients (pts). We c...
Breaking down barriers: Role of artificial intelligence in patient-friendly breast cancer education.
e13721 Background: Breast cancer is the most common cancer and is the second leading cause of cancer death in women in the United States. Adequate and eff...
REMATCH2201: A phase II study on reducing surgical margins in HPV-negative advanced HNSCC with neoadjuvant PD-1 inhibitor and AP chemotherapy.
6011 Background: The standard of care for resectable HNSCC includes extensive surgical margins to ensure complete oncologic resection, often at the expens...
Left atrial appendage closure (LAAC) in cancer patients: A systematic review and meta-analysis.
e24010 Background: Cancer increases the risk of atrial fibrillation (AF), particularly in patients over 65 or those with pre-existing cardiovascular disea...
A randomized trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer (ARIADNE).
TPS631 Background: Neoadjuvant therapy is the standard of care for the treatment of non-metastatic HER2-positive breast cancer. Studies on first generatio...
Predicting overall survival in adults with cancer in the US using machine learning approaches integrating comprehensive social risk factors.
1638 Background: Adults with cancer in the U.S. face an elevated mortality risk compared to the general population, with social risk factors playing a cri...
PET metabolic response in Lugano: Comparison of qualitative and quantitative outcome by independent central review.
7065 Background: The 2014 Lugano Criteria is the standard for radiographic assessment in lymphoma clinical trials, emphasizing qualitative evaluation of 1...
Meta-analysis of 55 studies examining the association between BMI and lung cancer risk in non-smokers.
e22551 Background: Lung cancer remains a leading cause of cancer-related mortality worldwide, with well-established risk factors such as smoking and envir...
A phase 1, first-in-human study of AMT-676, an anti-CDH17 antibody-drug conjugate, in patients with advanced gastrointestinal tumors.
TPS3161 Background: Cadherin-17 (CDH17), also known as liver-intestine-cadherin, is a transmembrane protein that is highly expressed in a variety of gastr...
Association of clinical characteristics with the use of proteomic testing for lung nodule malignancy risk stratification at a safety-net hospital.
e20036 Background: The NodifyLung CDT and XL2 tests use proteomics to risk stratify lung nodules. This test has emerged as a valuable tool in facilitating...
Development of a culturally tailored educational tool designed to increase access to somatic testing among Black men with metastatic prostate cancer (mPCa).
1591 Background: Somatic testing (ST), also known as molecular profiling, has become increasingly important for therapy selection in men with mPCa. Interv...
Clinicopathologic features of complement activation signatures in colorectal cancer.
3573 Background: Activation of the complement cascade pathway is associated with pro-oncogenic inflammation and immune-suppressing, myeloid-derived M2 mac...